БЕНЕТ Лесли З. (US),ДАЛЗИЛ Гена (US),ДИН Брайан (US),ДРЕССЕР Марк (US),ФРАЙМОЙЕР Адам (US),ХОЛДЕН Скотт (US),ЦЗИНЬ Цзинь (US),УЭР Джозеф А. (US)
申请号：
RU2014118490/15
公开号：
RU2014118490A
申请日:
2012.10.12
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating a hyperproliferative disorder, comprising administering a compound for re-acidification and GDC-0941, characterized by the formula: to a patient receiving a gastric acid-lowering therapeutic agent selected from a proton pump inhibitor, an H2 receptor antagonist and an antacid. 2. A method according to claim 1, wherein the compound for re-acidification is selected from betaine hydrochloride and glutamic acid hydrochloride. The method of claim 1, wherein the proton pump inhibitor is selected from omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole. The method of claim 1, further comprising determining a gastrin content or concentration of a GDC-0941 sample from a patient. The method of claim 1, wherein the patient is characterized by a hyperproliferative disorder. The method of claim 1, wherein the hyperproliferative disorder is a solid tumor or hematologic malignant disease. A method according to claim 1, wherein the bioavailability of GDC-0941 in a patient is higher than with the administration of GDC-0941 and a gastric acid-reducing therapeutic agent without a compound for re-acidification. The method according to claim 1, wherein the pH of the gastric juice in the patient is lower than with the administration of GDC-0941 and a gastric acid-lowering therapeutic agent without a compound for re-acidification. The method of claim 1, wherein the GDC-0941 and the compound for re-acidification are formulated in an oral dosage form. A method for enhancing the bioavailability of GDC-0941, characterized by the formula: comprising co-administration to a patient receiving a gastric acid-lowering therapeutic agent, e�1. Способ лечения гиперпролиферативного нарушения, включающий введение соединения для повторной ацидификации и GDC-0941, характеризующегося формулой:,пациенту, получающему снижающее кислотность желудочного сока терапевтическое средство, выбранное из ингибитора протонной помпы, антагониста Н2-рецептора и антацида.2. Способ п
